113 related articles for article (PubMed ID: 19189656)
41. Differential effects of low- and high-dose GW2974, a dual epidermal growth factor receptor and HER2 kinase inhibitor, on glioblastoma multiforme invasion.
Wang L; Liu Q; Zhao H; Cui K; Yao L; Nie F; Jin G; Hao A; Wong ST
J Neurosci Res; 2013 Jan; 91(1):128-37. PubMed ID: 23115024
[TBL] [Abstract][Full Text] [Related]
42. Epidermal growth factor receptor tyrosine kinase inhibition represses cyclin D1 in aerodigestive tract cancers.
Petty WJ; Dragnev KH; Memoli VA; Ma Y; Desai NB; Biddle A; Davis TH; Nugent WC; Memoli N; Hamilton M; Iwata KK; Rigas JR; Dmitrovsky E
Clin Cancer Res; 2004 Nov; 10(22):7547-54. PubMed ID: 15569985
[TBL] [Abstract][Full Text] [Related]
43. Gene expression changes associated with erlotinib response in glioma cell lines.
García-Claver A; Lorente M; Mur P; Campos-Martín Y; Mollejo M; Velasco G; Meléndez B
Eur J Cancer; 2013 May; 49(7):1641-53. PubMed ID: 23374632
[TBL] [Abstract][Full Text] [Related]
44. Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain.
Lee JC; Vivanco I; Beroukhim R; Huang JH; Feng WL; DeBiasi RM; Yoshimoto K; King JC; Nghiemphu P; Yuza Y; Xu Q; Greulich H; Thomas RK; Paez JG; Peck TC; Linhart DJ; Glatt KA; Getz G; Onofrio R; Ziaugra L; Levine RL; Gabriel S; Kawaguchi T; O'Neill K; Khan H; Liau LM; Nelson SF; Rao PN; Mischel P; Pieper RO; Cloughesy T; Leahy DJ; Sellers WR; Sawyers CL; Meyerson M; Mellinghoff IK
PLoS Med; 2006 Dec; 3(12):e485. PubMed ID: 17177598
[TBL] [Abstract][Full Text] [Related]
45. A urokinase receptor-Bim signaling axis emerges during EGFR inhibitor resistance in mutant EGFR glioblastoma.
Wykosky J; Hu J; Gomez GG; Taylor T; Villa GR; Pizzo D; VandenBerg SR; Thorne AH; Chen CC; Mischel PS; Gonias SL; Cavenee WK; Furnari FB
Cancer Res; 2015 Jan; 75(2):394-404. PubMed ID: 25432173
[TBL] [Abstract][Full Text] [Related]
46. Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours.
Halatsch ME; Schmidt U; Behnke-Mursch J; Unterberg A; Wirtz CR
Cancer Treat Rev; 2006 Apr; 32(2):74-89. PubMed ID: 16488082
[TBL] [Abstract][Full Text] [Related]
47. Erlotinib: early clinical development in brain cancer.
Addeo R; Zappavigna S; Parlato C; Caraglia M
Expert Opin Investig Drugs; 2014 Jul; 23(7):1027-37. PubMed ID: 24836441
[TBL] [Abstract][Full Text] [Related]
48. EGFR signaling is differentially activated in patient-derived glioblastoma stem cells.
Howard BM; Gursel DB; Bleau AM; Beyene RT; Holland EC; Boockvar JA
J Exp Ther Oncol; 2010; 8(3):247-60. PubMed ID: 20734923
[TBL] [Abstract][Full Text] [Related]
49. Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240.
Fenton TR; Nathanson D; Ponte de Albuquerque C; Kuga D; Iwanami A; Dang J; Yang H; Tanaka K; Oba-Shinjo SM; Uno M; Inda MM; Wykosky J; Bachoo RM; James CD; DePinho RA; Vandenberg SR; Zhou H; Marie SK; Mischel PS; Cavenee WK; Furnari FB
Proc Natl Acad Sci U S A; 2012 Aug; 109(35):14164-9. PubMed ID: 22891331
[TBL] [Abstract][Full Text] [Related]
50. HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme.
Raizer JJ
J Neurooncol; 2005 Aug; 74(1):77-86. PubMed ID: 16078112
[TBL] [Abstract][Full Text] [Related]
51. Combined inhibition of HER1/EGFR and RAC1 results in a synergistic antiproliferative effect on established and primary cultured human glioblastoma cells.
Karpel-Massler G; Westhoff MA; Zhou S; Nonnenmacher L; Dwucet A; Kast RE; Bachem MG; Wirtz CR; Debatin KM; Halatsch ME
Mol Cancer Ther; 2013 Sep; 12(9):1783-95. PubMed ID: 23832120
[TBL] [Abstract][Full Text] [Related]
52. Glioblastoma multiforme and the epidermal growth factor receptor.
Friedman HS; Bigner DD
N Engl J Med; 2005 Nov; 353(19):1997-9. PubMed ID: 16282174
[No Abstract] [Full Text] [Related]
53. Personalized medicine for glioblastoma: current challenges and future opportunities.
Zhu JJ; Wong ET
Curr Mol Med; 2013 Mar; 13(3):358-67. PubMed ID: 23331008
[TBL] [Abstract][Full Text] [Related]
54. Autophagy inhibition cooperates with erlotinib to induce glioblastoma cell death.
Eimer S; Belaud-Rotureau MA; Airiau K; Jeanneteau M; Laharanne E; Véron N; Vital A; Loiseau H; Merlio JP; Belloc F
Cancer Biol Ther; 2011 Jun; 11(12):1017-27. PubMed ID: 21508666
[TBL] [Abstract][Full Text] [Related]
55. Hyaluronic acid-functionalized gelatin hydrogels reveal extracellular matrix signals temper the efficacy of erlotinib against patient-derived glioblastoma specimens.
Pedron S; Wolter GL; Chen JE; Laken SE; Sarkaria JN; Harley BAC
Biomaterials; 2019 Oct; 219():119371. PubMed ID: 31352310
[TBL] [Abstract][Full Text] [Related]
56. Epithelial growth factor receptor expression influences 5-ALA induced glioblastoma fluorescence.
Fontana AO; Piffaretti D; Marchi F; Burgio F; Faia-Torres AB; Paganetti P; Pinton S; Pieles U; Reinert M
J Neurooncol; 2017 Jul; 133(3):497-507. PubMed ID: 28500562
[TBL] [Abstract][Full Text] [Related]
57. Response of glioblastomas to EGFR kinase inhibitors.
Lassman AB; Abrey LE; Gilbert MR
N Engl J Med; 2006 Feb; 354(5):525-6; author reply 525-6. PubMed ID: 16452568
[No Abstract] [Full Text] [Related]
58. The Hippo transducer TAZ promotes cell proliferation and tumor formation of glioblastoma cells through EGFR pathway.
Yang R; Wu Y; Zou J; Zhou J; Wang M; Hao X; Cui H
Oncotarget; 2016 Jun; 7(24):36255-36265. PubMed ID: 27167112
[TBL] [Abstract][Full Text] [Related]
59. Bioinformatics analysis reveals disturbance mechanism of MAPK signaling pathway and cell cycle in Glioblastoma multiforme.
Li W; Li K; Zhao L; Zou H
Gene; 2014 Sep; 547(2):346-50. PubMed ID: 24967941
[TBL] [Abstract][Full Text] [Related]
60. Somatic mutations of EGFR in colorectal cancers and glioblastomas.
Barber TD; Vogelstein B; Kinzler KW; Velculescu VE
N Engl J Med; 2004 Dec; 351(27):2883. PubMed ID: 15625347
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
